JP2022543060A5 - - Google Patents

Info

Publication number
JP2022543060A5
JP2022543060A5 JP2022506472A JP2022506472A JP2022543060A5 JP 2022543060 A5 JP2022543060 A5 JP 2022543060A5 JP 2022506472 A JP2022506472 A JP 2022506472A JP 2022506472 A JP2022506472 A JP 2022506472A JP 2022543060 A5 JP2022543060 A5 JP 2022543060A5
Authority
JP
Japan
Prior art keywords
tcr
amino acid
mage
acid sequence
constant region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022506472A
Other languages
English (en)
Japanese (ja)
Other versions
JP7669347B2 (ja
JP2022543060A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/057177 external-priority patent/WO2021019477A1/en
Publication of JP2022543060A publication Critical patent/JP2022543060A/ja
Publication of JP2022543060A5 publication Critical patent/JP2022543060A5/ja
Application granted granted Critical
Publication of JP7669347B2 publication Critical patent/JP7669347B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022506472A 2019-07-30 2020-07-29 T細胞受容体及びその使用方法 Active JP7669347B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962880508P 2019-07-30 2019-07-30
US62/880,508 2019-07-30
PCT/IB2020/057177 WO2021019477A1 (en) 2019-07-30 2020-07-29 T cell receptors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022543060A JP2022543060A (ja) 2022-10-07
JP2022543060A5 true JP2022543060A5 (cg-RX-API-DMAC7.html) 2023-08-08
JP7669347B2 JP7669347B2 (ja) 2025-04-28

Family

ID=74229599

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506472A Active JP7669347B2 (ja) 2019-07-30 2020-07-29 T細胞受容体及びその使用方法

Country Status (12)

Country Link
US (1) US20220275046A1 (cg-RX-API-DMAC7.html)
EP (1) EP4004218A4 (cg-RX-API-DMAC7.html)
JP (1) JP7669347B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220038776A (cg-RX-API-DMAC7.html)
CN (1) CN114364806B (cg-RX-API-DMAC7.html)
AU (1) AU2020322247A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022001697A2 (cg-RX-API-DMAC7.html)
CA (1) CA3146303A1 (cg-RX-API-DMAC7.html)
IL (1) IL290228A (cg-RX-API-DMAC7.html)
MX (1) MX2022001206A (cg-RX-API-DMAC7.html)
TW (1) TWI869426B (cg-RX-API-DMAC7.html)
WO (1) WO2021019477A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020231693A1 (en) 2019-03-04 2021-09-30 University Health Network T cell receptors and methods of use thereof
WO2021019472A1 (en) 2019-07-30 2021-02-04 University Health Network T cell receptors and methods of use thereof
AU2020320129A1 (en) 2019-07-30 2022-03-03 University Health Network T cell receptors and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
EP3031916B1 (en) * 2007-06-11 2017-06-07 Takara Bio Inc. Method for expression of specific gene
WO2012054825A1 (en) * 2010-10-22 2012-04-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mage-a3 t cell receptors and related materials and methods of use
CA2912389C (en) * 2013-06-10 2020-01-28 The General Hospital Corporation D/B/A Massachusetts General Hospital Methods and compositions for reducing immunosupression by tumor cells
JP2019521080A (ja) * 2016-04-27 2019-07-25 ユニバーシティ・ヘルス・ネットワーク ペプチド−hla複合体およびその産生方法
GB2573069A (en) * 2016-12-16 2019-10-23 Twist Bioscience Corp Variant libraries of the immunological synapse and synthesis thereof
EA201991444A1 (ru) * 2017-01-27 2019-12-30 Имматикс Байотекнолоджиз Гмбх Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
WO2019046856A1 (en) * 2017-09-04 2019-03-07 Agenus Inc. T-CELL RECEPTORS THAT BIND TO SPECIFIC PHOSPHOPEPTIDES OF MIXED LINEAR LEUKEMIA (MLL) AND METHODS OF USE THEREOF
CA3076337A1 (en) * 2017-09-19 2019-03-28 Massachusetts Institute Of Technology Compositions for chimeric antigen receptor t cell therapy and uses thereof
WO2019222275A2 (en) * 2018-05-14 2019-11-21 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using inducible fusion proteins
GB201814362D0 (en) * 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
CA3127673A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras

Similar Documents

Publication Publication Date Title
JP2022527267A5 (cg-RX-API-DMAC7.html)
JP2022523971A5 (cg-RX-API-DMAC7.html)
JP2022523552A5 (cg-RX-API-DMAC7.html)
JP2022524993A5 (cg-RX-API-DMAC7.html)
JP2022524994A5 (cg-RX-API-DMAC7.html)
JP2022523554A5 (cg-RX-API-DMAC7.html)
JP2022523553A5 (cg-RX-API-DMAC7.html)
JP2022524992A5 (cg-RX-API-DMAC7.html)
JP2022543059A5 (cg-RX-API-DMAC7.html)
Kershaw et al. Gene-engineered T cells for cancer therapy
JP2022169543A (ja) 改善された養子t細胞療法
US20190117692A1 (en) Engager cells for immunotherapy
RU2018147423A (ru) Анти-PD-L1 и IL-2 цитокины
AU2019243448A1 (en) Guidance and navigation control proteins and method of making and using thereof
JP2022543058A5 (cg-RX-API-DMAC7.html)
JP2022521183A5 (cg-RX-API-DMAC7.html)
CN108138148A (zh) T细胞的激活和扩增
JP2021512637A5 (cg-RX-API-DMAC7.html)
WO2021223720A1 (zh) 人源化cd19抗体及其应用
JP2020533962A5 (cg-RX-API-DMAC7.html)
IL301995A (en) Cells comprising t cell-antigen couplers and uses thereof
CA3117079A1 (en) Bispecific polypeptides for engagement of car expressing immune cells with antigen presenting cells and uses thereof
JP2023542528A5 (cg-RX-API-DMAC7.html)
KR20250158012A (ko) 키메라 항원 수용체
JP2022547809A5 (cg-RX-API-DMAC7.html)